1. Intrathecal (i.t.) administration of
prostaglandin E2 (
PGE2) to conscious mice induced
allodynia, a state of discomfort and
pain evoked by innocuous tactile stimuli, and
hyperalgesia as assessed by the hot plate test. We characterized
prostaglandin E receptor subtypes (EP1-3) involved in these
sensory disorders by use of 7 synthetic
prostanoid analogues. 2.
Sulprostone (EP1 < EP3) induced
allodynia over a wide range of dosages from 50 pg to 5 micrograms kg-1. The maximal allodynic effect was observed at 5 min after i.t. injection, and the response gradually decreased over the experimental period of 50 min. This
sulprostone-induced
allodynia showed a time course similar to that induced by
PGE2. 3.
17-Phenyl-omega-trinor PGE2 (EP1 > EP3) and 16,16-dimethyl
PGE2 (EP1 = EP2 = EP3) were as potent as
PGE2 in inducing
allodynia, and more potent than
sulprostone.
Butaprost (EP2), 11-deoxy
PGE1 (EP2 = EP3), MB 28767 (EP3), and
cicaprost (
prostaglandin I2 (IP-) receptor) induced
allodynia, but with much lower scores. 13,14-Dihydro-15-keto
PGE2, a metabolite of
PGE2, did not induce
allodynia. 4. 16,16-Dimethyl
PGE2 as well as
PGE2 induced
hyperalgesia over a wide range of dosages (
16,16-dimethyl PGE2: 5 pg-0.5 micrograms kg-1
PGE2: 50 pg-0.5 micrograms kg-1) with two apparent peaks at 0.5 ng kg-1 and 0.5 micrograms kg-1.
Sulprostone (EP1 < EP3) and
17-phenyl-omega-trinor PGE2 (EP1 > EP3) showed a bell-shaped
hyperalgesia at lower doses of 5 pg-5 ng kg-1 and 50 pg-50 ng kg-1, respectively. MB28767 (EP3)showed a monophasic hyperalgesic action over a wide range of dosages at 50 pg-S5 Microg kg-1.
Butaprost(EP2) induced
hyperalgesia at doses higher than 50 ng kg-1.5. These results demonstrate that
PGE2 may exert
allodynia through the EP1-receptor and
hyperalgesia through EP2- and EP3-receptors in the mouse spinal cord.